Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Finding of rHuPH20 for SC IGIV in PID
NCT00782106Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2006
- Primary completion
- Nov 2007
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human hyaluronidase PH20 in primary immunodeficiency diseases (PID) (2 arms), sponsored by Takeda. Primary endpoint: Ability to administer at least one half of a 4-week dose of IgG in a single infusion site via the subcutaneous route at 72 hours. Started Dec 2006; status: completed.
02
Drugs
recombinant human hyaluronidase PH20
03
Conditions
primary immunodeficiency diseases (PID)
Beyond the preview
Go deeper on NCT00782106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782106.